Global Bovine Ephemeral Fever Vaccines Market

Bovine Ephemeral Fever Vaccines Comprehensive Study by Application (Cattle, Buffaloes), Vaccine Type (Live Vaccine, Killed Vaccine), End User (Medical Device Companies, Pharmaceutical industries, Animal Hospitals, Other End Users), Conditions (Traumatic Reticulitis, Acute Laminitis, Parturient Paresis) Players and Region - Global Market Outlook to 2026

Bovine Ephemeral Fever Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Bovine Ephemeral Fever Vaccines Market Overview:
Bovine ephemeral fever (BEF or Bovine Epizootic Fever) is a noncontagious arthropod-borne disease of cattle, characterized by an acute fever of short duration, with high morbidity and low mortality. BEF is a short fever leading to shivering, lameness, and muscular stiffness in animals. This is an important arboviral disease affecting cattle, yaks, and water buffalo in East Asia and Northern Australia where it causes serious economic losses. Vaccination is widely provided through both modified live and killed vaccines. They should be given in two doses, two to six weeks apart, well before the start of the mosquito and sand-fly season.

Growth Drivers
  • Increasing Demand From Pharmaceutical Companies
  • Rising Incidence Of Bovine Ephemeral Fever (BEF)

Market Trends
  • Geriatric Inhabitant Across The Globe

Roadblocks
  • Lack Of Knowledge About Vaccine In Rural Areas

Opportunities
  • Increase In R&D In The Field Of Vaccines
  • Growing Number Of Companies Providing Healthcare Services And Vaccines

Challenges
  • Availability Of Vaccines


Competitive Landscape:
The global bovine ephemeral fever vaccines market is largely competitive and consists of the limited number of vendors. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant risk factors for the growth of bovine ephemeral fever vaccine providers.
Some of the key players profiled in the report are Zoetis Inc. (United States), Onderstepoort Biological Products SOC Ltd (South Africa), Nutri Pharmax Sdn Bhd (Malaysia), Octavoscene (Pty) Ltd (South Africa), Kyoto Biken Laboratories, Inc. (Japan), Green Cross Veterinary Products Co. Ltd (South Korea), ChoongAng Vaccine Laboratories Co. Ltd (South Korea) and OBP Vaccines (South Africa). Considering Market by Vaccine Type, the sub-segment i.e. Live Vaccine will boost the Bovine Ephemeral Fever Vaccines market. Considering Market by End User , the sub-segment i.e. Medical Device Companies will boost the Bovine Ephemeral Fever Vaccines market. Considering Market by Conditions , the sub-segment i.e. Traumatic Reticulitis will boost the Bovine Ephemeral Fever Vaccines market.

What Can be Explored with the Bovine Ephemeral Fever Vaccines Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Bovine Ephemeral Fever Vaccines Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Bovine Ephemeral Fever Vaccines
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Bovine Ephemeral Fever Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Bovine Ephemeral Fever Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Bovine Ephemeral Fever Vaccines Providers, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Cattle
  • Buffaloes
By Vaccine Type
  • Live Vaccine
  • Killed Vaccine

By End User
  • Medical Device Companies
  • Pharmaceutical industries
  • Animal Hospitals
  • Other End Users

By Conditions
  • Traumatic Reticulitis
  • Acute Laminitis
  • Parturient Paresis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand From Pharmaceutical Companies
      • 3.2.2. Rising Incidence Of Bovine Ephemeral Fever (BEF)
    • 3.3. Market Challenges
      • 3.3.1. Availability Of Vaccines
    • 3.4. Market Trends
      • 3.4.1. Geriatric Inhabitant Across The Globe
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bovine Ephemeral Fever Vaccines, by Application, Vaccine Type, End User , Conditions and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bovine Ephemeral Fever Vaccines (Value)
      • 5.2.1. Global Bovine Ephemeral Fever Vaccines by: Application (Value)
        • 5.2.1.1. Cattle
        • 5.2.1.2. Buffaloes
      • 5.2.2. Global Bovine Ephemeral Fever Vaccines by: Vaccine Type (Value)
        • 5.2.2.1. Live Vaccine
        • 5.2.2.2. Killed Vaccine
      • 5.2.3. Global Bovine Ephemeral Fever Vaccines Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Bovine Ephemeral Fever Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Zoetis Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Onderstepoort Biological Products SOC Ltd (South Africa)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nutri Pharmax Sdn Bhd (Malaysia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octavoscene (Pty) Ltd (South Africa)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kyoto Biken Laboratories, Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Green Cross Veterinary Products Co. Ltd (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ChoongAng Vaccine Laboratories Co. Ltd (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. OBP Vaccines (South Africa)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Bovine Ephemeral Fever Vaccines Sale, by Application, Vaccine Type, End User , Conditions and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bovine Ephemeral Fever Vaccines (Value)
      • 7.2.1. Global Bovine Ephemeral Fever Vaccines by: Application (Value)
        • 7.2.1.1. Cattle
        • 7.2.1.2. Buffaloes
      • 7.2.2. Global Bovine Ephemeral Fever Vaccines by: Vaccine Type (Value)
        • 7.2.2.1. Live Vaccine
        • 7.2.2.2. Killed Vaccine
      • 7.2.3. Global Bovine Ephemeral Fever Vaccines Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bovine Ephemeral Fever Vaccines: by Application(USD Million)
  • Table 2. Bovine Ephemeral Fever Vaccines Cattle , by Region USD Million (2015-2020)
  • Table 3. Bovine Ephemeral Fever Vaccines Buffaloes , by Region USD Million (2015-2020)
  • Table 4. Bovine Ephemeral Fever Vaccines: by Vaccine Type(USD Million)
  • Table 5. Bovine Ephemeral Fever Vaccines Live Vaccine , by Region USD Million (2015-2020)
  • Table 6. Bovine Ephemeral Fever Vaccines Killed Vaccine , by Region USD Million (2015-2020)
  • Table 7. South America Bovine Ephemeral Fever Vaccines, by Country USD Million (2015-2020)
  • Table 8. South America Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 9. South America Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 10. South America Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 11. South America Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 12. Brazil Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 13. Brazil Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 14. Brazil Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 15. Brazil Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 16. Argentina Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 17. Argentina Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 18. Argentina Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 19. Argentina Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 20. Rest of South America Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 21. Rest of South America Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 22. Rest of South America Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 23. Rest of South America Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 24. Asia Pacific Bovine Ephemeral Fever Vaccines, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 26. Asia Pacific Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 27. Asia Pacific Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 28. Asia Pacific Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 29. China Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 30. China Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 31. China Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 32. China Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 33. Japan Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 34. Japan Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 35. Japan Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 36. Japan Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 37. India Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 38. India Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 39. India Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 40. India Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 41. South Korea Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 42. South Korea Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 43. South Korea Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 44. South Korea Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 45. Taiwan Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 46. Taiwan Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 47. Taiwan Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 48. Taiwan Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 49. Australia Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 50. Australia Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 51. Australia Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 52. Australia Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 57. Europe Bovine Ephemeral Fever Vaccines, by Country USD Million (2015-2020)
  • Table 58. Europe Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 59. Europe Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 60. Europe Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 61. Europe Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 62. Germany Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 63. Germany Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 64. Germany Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 65. Germany Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 66. France Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 67. France Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 68. France Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 69. France Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 70. Italy Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 71. Italy Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 72. Italy Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 73. Italy Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 74. United Kingdom Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 75. United Kingdom Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 76. United Kingdom Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 77. United Kingdom Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 78. Netherlands Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 79. Netherlands Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 80. Netherlands Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 81. Netherlands Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 82. Rest of Europe Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 83. Rest of Europe Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 84. Rest of Europe Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 85. Rest of Europe Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 86. MEA Bovine Ephemeral Fever Vaccines, by Country USD Million (2015-2020)
  • Table 87. MEA Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 88. MEA Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 89. MEA Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 90. MEA Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 91. Middle East Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 92. Middle East Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 93. Middle East Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 94. Middle East Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 95. Africa Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 96. Africa Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 97. Africa Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 98. Africa Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 99. North America Bovine Ephemeral Fever Vaccines, by Country USD Million (2015-2020)
  • Table 100. North America Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 101. North America Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 102. North America Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 103. North America Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 104. United States Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 105. United States Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 106. United States Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 107. United States Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 108. Canada Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 109. Canada Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 110. Canada Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 111. Canada Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 112. Mexico Bovine Ephemeral Fever Vaccines, by Application USD Million (2015-2020)
  • Table 113. Mexico Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2015-2020)
  • Table 114. Mexico Bovine Ephemeral Fever Vaccines, by End User USD Million (2015-2020)
  • Table 115. Mexico Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2015-2020)
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Bovine Ephemeral Fever Vaccines: by Application(USD Million)
  • Table 125. Bovine Ephemeral Fever Vaccines Cattle , by Region USD Million (2021-2026)
  • Table 126. Bovine Ephemeral Fever Vaccines Buffaloes , by Region USD Million (2021-2026)
  • Table 127. Bovine Ephemeral Fever Vaccines: by Vaccine Type(USD Million)
  • Table 128. Bovine Ephemeral Fever Vaccines Live Vaccine , by Region USD Million (2021-2026)
  • Table 129. Bovine Ephemeral Fever Vaccines Killed Vaccine , by Region USD Million (2021-2026)
  • Table 130. South America Bovine Ephemeral Fever Vaccines, by Country USD Million (2021-2026)
  • Table 131. South America Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 132. South America Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 133. South America Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 134. South America Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 135. Brazil Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 136. Brazil Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 137. Brazil Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 138. Brazil Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 139. Argentina Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 140. Argentina Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 141. Argentina Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 142. Argentina Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 143. Rest of South America Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 144. Rest of South America Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 145. Rest of South America Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 146. Rest of South America Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 147. Asia Pacific Bovine Ephemeral Fever Vaccines, by Country USD Million (2021-2026)
  • Table 148. Asia Pacific Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 149. Asia Pacific Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 150. Asia Pacific Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 151. Asia Pacific Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 152. China Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 153. China Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 154. China Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 155. China Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 156. Japan Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 157. Japan Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 158. Japan Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 159. Japan Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 160. India Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 161. India Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 162. India Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 163. India Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 164. South Korea Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 165. South Korea Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 166. South Korea Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 167. South Korea Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 168. Taiwan Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 169. Taiwan Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 170. Taiwan Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 171. Taiwan Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 172. Australia Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 173. Australia Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 174. Australia Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 175. Australia Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 176. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 177. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 178. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 179. Rest of Asia-Pacific Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 180. Europe Bovine Ephemeral Fever Vaccines, by Country USD Million (2021-2026)
  • Table 181. Europe Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 182. Europe Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 183. Europe Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 184. Europe Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 185. Germany Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 186. Germany Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 187. Germany Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 188. Germany Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 189. France Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 190. France Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 191. France Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 192. France Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 193. Italy Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 194. Italy Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 195. Italy Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 196. Italy Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 197. United Kingdom Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 198. United Kingdom Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 199. United Kingdom Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 200. United Kingdom Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 201. Netherlands Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 202. Netherlands Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 203. Netherlands Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 204. Netherlands Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 205. Rest of Europe Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 206. Rest of Europe Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 207. Rest of Europe Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 208. Rest of Europe Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 209. MEA Bovine Ephemeral Fever Vaccines, by Country USD Million (2021-2026)
  • Table 210. MEA Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 211. MEA Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 212. MEA Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 213. MEA Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 214. Middle East Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 215. Middle East Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 216. Middle East Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 217. Middle East Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 218. Africa Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 219. Africa Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 220. Africa Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 221. Africa Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 222. North America Bovine Ephemeral Fever Vaccines, by Country USD Million (2021-2026)
  • Table 223. North America Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 224. North America Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 225. North America Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 226. North America Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 227. United States Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 228. United States Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 229. United States Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 230. United States Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 231. Canada Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 232. Canada Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 233. Canada Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 234. Canada Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 235. Mexico Bovine Ephemeral Fever Vaccines, by Application USD Million (2021-2026)
  • Table 236. Mexico Bovine Ephemeral Fever Vaccines, by Vaccine Type USD Million (2021-2026)
  • Table 237. Mexico Bovine Ephemeral Fever Vaccines, by End User USD Million (2021-2026)
  • Table 238. Mexico Bovine Ephemeral Fever Vaccines, by Conditions USD Million (2021-2026)
  • Table 239. Research Programs/Design for This Report
  • Table 240. Key Data Information from Secondary Sources
  • Table 241. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bovine Ephemeral Fever Vaccines: by Application USD Million (2015-2020)
  • Figure 5. Global Bovine Ephemeral Fever Vaccines: by Vaccine Type USD Million (2015-2020)
  • Figure 6. South America Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 7. Asia Pacific Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 8. Europe Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 9. MEA Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 10. North America Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 11. Global Bovine Ephemeral Fever Vaccines share by Players 2020 (%)
  • Figure 12. Global Bovine Ephemeral Fever Vaccines share by Players (Top 3) 2020(%)
  • Figure 13. Global Bovine Ephemeral Fever Vaccines share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Zoetis Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Zoetis Inc. (United States) Revenue: by Geography 2020
  • Figure 17. Onderstepoort Biological Products SOC Ltd (South Africa) Revenue, Net Income and Gross profit
  • Figure 18. Onderstepoort Biological Products SOC Ltd (South Africa) Revenue: by Geography 2020
  • Figure 19. Nutri Pharmax Sdn Bhd (Malaysia) Revenue, Net Income and Gross profit
  • Figure 20. Nutri Pharmax Sdn Bhd (Malaysia) Revenue: by Geography 2020
  • Figure 21. Octavoscene (Pty) Ltd (South Africa) Revenue, Net Income and Gross profit
  • Figure 22. Octavoscene (Pty) Ltd (South Africa) Revenue: by Geography 2020
  • Figure 23. Kyoto Biken Laboratories, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Kyoto Biken Laboratories, Inc. (Japan) Revenue: by Geography 2020
  • Figure 25. Green Cross Veterinary Products Co. Ltd (South Korea) Revenue, Net Income and Gross profit
  • Figure 26. Green Cross Veterinary Products Co. Ltd (South Korea) Revenue: by Geography 2020
  • Figure 27. ChoongAng Vaccine Laboratories Co. Ltd (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. ChoongAng Vaccine Laboratories Co. Ltd (South Korea) Revenue: by Geography 2020
  • Figure 29. OBP Vaccines (South Africa) Revenue, Net Income and Gross profit
  • Figure 30. OBP Vaccines (South Africa) Revenue: by Geography 2020
  • Figure 31. Global Bovine Ephemeral Fever Vaccines: by Application USD Million (2021-2026)
  • Figure 32. Global Bovine Ephemeral Fever Vaccines: by Vaccine Type USD Million (2021-2026)
  • Figure 33. South America Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 34. Asia Pacific Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 35. Europe Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 36. MEA Bovine Ephemeral Fever Vaccines Share (%), by Country
  • Figure 37. North America Bovine Ephemeral Fever Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Zoetis Inc. (United States)
  • Onderstepoort Biological Products SOC Ltd (South Africa)
  • Nutri Pharmax Sdn Bhd (Malaysia)
  • Octavoscene (Pty) Ltd (South Africa)
  • Kyoto Biken Laboratories, Inc. (Japan)
  • Green Cross Veterinary Products Co. Ltd (South Korea)
  • ChoongAng Vaccine Laboratories Co. Ltd (South Korea)
  • OBP Vaccines (South Africa)
Select User Access Type

Key Highlights of Report


Apr 2021 211 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bovine Ephemeral Fever Vaccines Market Quantitative research analysis
Global Bovine Ephemeral Fever Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Bovine Ephemeral Fever Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Dental Resin Composites Comprehensive Study by Type (Bulk fill composite, Universal composite, Flowable composite, Others), Application (Dental fillings, Dental crowns, Dental bridges, Others), Compo...
$ 3750
Ocaliva Comprehensive Study by Application (Primary Biliary Cirrhosis, Non-alcoholic Fatty Liver Disease, Other), Distribution Channel (Online, Offline), End-User (Hospitals, Cancer Centres, Others),...
$ 3350
Lithium Medication Comprehensive Study by Type (Tablets, Capsules, Oral Solution), Application (Hospitals, Clinics, Others), Distribution Channel (Online Pharmacies, Retail Pharmacies, Online, Others...
$ 3500
Dietary Supplements Ingredients Comprehensive Study by Type (Andarine, Higenamine, Octopamine, Sodium Tetrachloroaurate, Cesium Chloride, Others), Application (Additional Supplements, Medicinal Suppl...
$ 3450
Glatiramer Comprehensive Study by Type (Brand Medicine, Generic Drug), Application (Hospital, Pharmacy, Other), Route of Administration (Enteral Route, Parenteral Route), Intake Form (Alone, With Oth...
$ 3500
Metformin Drugs Comprehensive Study by Type (Metformin-Alogliptin, Metformin-Canagliflozin, Metformin-Dapagliflozin, Metformin-Empagliflozin, Others), Category (Immediate Release, Extended Release), ...
$ 3650